Im­prim­is spins out a new biotech fo­cused on eye drugs; Alzheimer’s groups back PhII study at Amy­lyx

→ San Diego-based Im­prim­is has set up a new sub­sidiary to pur­sue the de­vel­op­ment of new drugs for eye dis­eases. And the com­pa­ny has tapped Kam­ran Hos­sei­ni to run the op­er­a­tion — Sur­face Phar­ma­ceu­ti­cals — as the CEO.

→ The Alzheimer’s As­so­ci­a­tion and the Alzheimer’s Drug Dis­cov­ery Foun­da­tion are help­ing fund a new com­bi­na­tion ther­a­py for Alzheimer’s by Amy­lyx Phar­ma­ceu­ti­cals. Their $1.85 mil­lion grant will sup­port a small Phase II study with 50 pa­tients, who will be treat­ed with AMX0035, a com­bi­na­tion of sodi­um phenyl­bu­tyrate and tau­rour­sodeoxy­cholic-acid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER